Lab Genomics, Canexia secure MolDX coverage for DNA assay

LabPulse.com staff writers
Nov 1, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400

Lab Genomics and Canexia Health have secured molecular diagnostic services (MolDX) coverage for Canexia Health's Follow It circulating tumor DNA (ctDNA) assay, which uses blood drawn from patients to analyze ctDNA in plasma.

The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.

Latest in Colorectal Cancer
Lawsuit Social
Geneoscopy requests review of Exact Sciences patent, dismissal of lawsuit
January 12, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Fda Button Social
FDA grants approval to Takeda’s metastatic colorectal cancer therapy
November 9, 2023
Colorectal Cancer Social
Researchers engineer bacterial biosensor that can detect tumor DNA
August 14, 2023
Related Stories
2019 10 01 18 58 9423 Colon2 400
Colorectal Cancer
DiaCarta touts results from ColoScape assay in colon cancer
2019 08 12 20 23 3708 Lab Blood Centrifuge 400
Colorectal Cancer
Natera and BGI launch new assay in China
2019 11 04 19 56 0311 Colorectal Cancer 400
Colorectal Cancer
Solvd Health to start colorectal cancer test study
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Colorectal Cancer
Geneoscopy requests review of Exact Sciences patent, dismissal of lawsuit
By LabPulse.com staff writers
In the latest development in the patent infringement dispute between the two companies, Geneoscopy has petitioned the U.S. Patent and Trademark Office for inter partes review, challenging the patent in contention held by Exact Sciences.
January 12, 2024
Lawsuit Social
Universal DX partners with Quest Diagnostics, closes $70M series B financing round
By LabPulse.com staff writers
Liquid biopsy firm Universal DX and Quest Diagnostics have formed a strategic collaboration under which Quest will exclusively offer services for Universal DX’s Signal-C colorectal cancer screening test in the U.S.
November 21, 2023
Colorectal Cancer Social
FDA grants approval to Takeda’s metastatic colorectal cancer therapy
By LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has approved a chemotherapy-free oral target therapy for patients who have been previously treated for metastatic colorectal cancer (mCRC).
November 9, 2023
Fda Button Social
Researchers engineer bacterial biosensor that can detect tumor DNA
By LabPulse.com staff writers
The technique, dubbed Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer and known by the acronym CATCH, was designed to identify specific DNA sequences and mutations outside of cells.
August 14, 2023
Colorectal Cancer Social
Exact Sciences raises full-year guidance due to demand for colorectal cancer test
By Nick Paul Taylor
Revenues for Exact Sciences’ screening business, which sells the Cologuard colorectal cancer stool test, increased by 31% to $462.8 million in the second quarter.
August 10, 2023
Colon Intestine Social
New Day Diagnostics inks $12M deal to buy Epigenomics’ cancer technology
By Nick Paul Taylor
Epigenomics has agreed to sell “substantially all” of its assets to New Day Diagnostics, a developer of tests for the early detection and monitoring of disease that merged with EDP Biotech earlier this month.
July 31, 2023
Colon Disease Social
Harvard Medical School, RareCyte developing multiplex imaging for clinical pathology
By Elissa Wolfson
Multiplex imaging technology enables the integration of microscopic analysis with the visualization of molecular markers in individual cells.
June 26, 2023
Scientists Lab Microscope Social
Next-gen Cologuard demonstrates 94% sensitivity, 91% specificity for colorectal cancer detection
By Leo O'Connor
The firm also entered collaborations related to next-generation technology for ultra-sensitive detection of molecular residual disease (MRD) and ongoing research, as well as for the development of its multicancer early detection (MCED) approach.
June 21, 2023
Exact Sciences Corporation Social
Colorectal cancer growth and chemoresistance linked to specific protein in study
By Elissa Wolfson
Colorectal cancer grows faster and becomes more resistant to common chemotherapy drugs when elevated levels of a specific protein are present.
June 16, 2023
Colorectal Cancer Social
Genetic counseling may boost colorectal cancer patient empowerment: Study
By Elissa Wolfson
A randomized controlled genetic counseling trial for those affected by colorectal cancer showed significant improvements in patient empowerment.
June 12, 2023
Doctor Patient Consult Tablet Social
Polygenic risk scores may improve colorectal cancer screening
By Elissa Wolfson
Polygenic risk scores may identify individuals at high risk of developing colorectal cancer, improving current screening strategies for the disease.
June 12, 2023
Dna Genome Gene Targeted Social
Bacteria vary between early- and late-onset colorectal cancer tumors: Study
By Elissa Wolfson
Bacteria types vary widely between early- versus late-onset colorectal cancer tumors, providing clues to the disease’s increase in younger people, according to a study.
May 30, 2023
Colorectal Cancer Social
Page 1 of 6
Next Page